{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:30:20Z","timestamp":1790213420313,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To define meropenem plasma concentrations and pharmacodynamic exposure metrics in children with septic shock during the first 3 days of PICU hospitalization.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Pharmacokinetic sampling was undertaken in 19 subjects receiving standard meropenem dosing (20\u2009mg\/kg\/dose, 8\u2009hr) recruited from March 2019 to March 2022. Sampling occurred once each day following meropenem given 24 hours apart, during the first 3 PICU days. Data analysis was completed in 2023 and noncompartmental analysis was performed to assess pharmacodynamic exposure targets for sepsis. Clearance and volume of distribution at 20\u2009mg\/kg\/dose were used to simulate mean exposures at 40 and 60\u2009mg\/kg\/dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>PICU in a tertiary care center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SUBJECTS:<\/jats:title>\n            <jats:p>Patients 4 weeks old or older with hypotension requiring fluid resuscitation and vasopressor therapy, receiving meropenem as empiric therapy for sepsis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>Augmented renal clearance (ARC) was documented in eight of 19 subjects, previously associated with subtherapeutic plasma concentrations, while three of 19 had acute kidney injury and decreased renal clearance. When assessed by pharmacodynamic exposure targets for sepsis (plasma meropenem concentrations above the minimum inhibitory concentration [MIC] of <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> for 70% or 100% of the dosing interval), ten of 19 and nine of 19 children, respectively, had subtherapeutic plasma meropenem exposures during PICU day 1, even for pathogens with an MIC considered \u201csusceptible\u201d by U.S. Food and Drug Administration criteria. Therapeutic meropenem pharmacodynamic exposures were associated with a positive 24-hour fluid balance on PICU day 1 and a negative 24-hour fluid balance by day 3, although profound variability was noted in fluid administered and renal output.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Given the variability in meropenem systemic exposure in pediatric septic shock, therapeutic drug monitoring, or monitoring for ARC, is suggested during the first days of hospitalization to allow daily assessments of dosing needs to achieve pharmacodynamic exposure targets for sepsis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pcc.0000000000003698","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T15:00:12Z","timestamp":1739890812000},"page":"e507-e515","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Subtherapeutic Meropenem Antibiotic Exposure in Children With Septic Shock Assessed by Noncompartmental Pharmacokinetic Analysis in a Prospective Dataset"],"prefix":"10.1097","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5064","authenticated-orcid":false,"given":"John S.","family":"Bradley","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA."},{"name":"Division of Infectious Diseases, Rady Children\u2019s Hospital of San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Harvey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Critical Care, University of California San Diego, and Rady Children\u2019s Hospital, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayna","family":"Stout","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Rady Children\u2019s Hospital of San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Momper","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean N.","family":"Avedissian","sequence":"additional","affiliation":[{"name":"Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Barbato","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom P.","family":"Jones","sequence":"additional","affiliation":[{"name":"Certara, Godfrey, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Critical Care, University of California San Diego, and Rady Children\u2019s Hospital, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"R1-20250410","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1378\/chest.115.2.462","article-title":"Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients.","volume":"115","author":"Kollef","year":"1999","journal-title":"Chest"},{"key":"R2-20250410","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinantof survival in human septic shock.","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit Care Med"},{"key":"R3-20250410","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: Results from a guideline-based performance improvement program.","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"key":"R4-20250410","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: A systematic review.","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R5-20250410","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijantimicag.2012.05.010","article-title":"Decreased meropenem levels in intensive care unit patients with augmented renal clearance: Benefit of therapeutic drug monitoring.","volume":"40","author":"Troger","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R6-20250410","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study.","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R7-20250410","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1128\/AAC.01368-15","article-title":"Augmented renal clearance implies a need for increased amoxicillin-clavulanic acid dosing in critically ill children.","volume":"59","author":"De Cock","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-20250410","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/PCC.0000000000001228","article-title":"Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients.","volume":"18","author":"Avedissian","year":"2017","journal-title":"Pediatr Crit Care Med"},{"key":"R9-20250410","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions.","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R10-20250410","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of \u2018bug and drug.\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"R11-20250410","doi-asserted-by":"crossref","first-page":"e02309","DOI":"10.1128\/AAC.02309-18","article-title":"Considerations for dose selection and clinical pharmacokinetics\/pharmacodynamics for the development of antibacterial agents.","volume":"63","author":"Rizk","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250410","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections.","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R13-20250410","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R14-20250410","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: Defining antibiotic levels in intensive care unit patients: Are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R15-20250410","doi-asserted-by":"crossref","first-page":"ofad500.2168","DOI":"10.1093\/ofid\/ofad500.2168","article-title":"2551. Assessing meropenem concentrations in children with septic shock: Population-based pharmacokinetic (PK) modeling of meropenem demonstrates variability from acute kidney (AKI) to augmented renal clearance (ARC).","volume":"10","author":"Le","year":"2023","journal-title":"Open Forum Infectious Dis"},{"key":"R16-20250410","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","article-title":"Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance.","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R17-20250410","first-page":"413","article-title":"Use of simulation strategies to predict subtherapeutic meropenem exposure caused by augmented renal clearance in critically ill pediatric patients with sepsis.","volume":"25","author":"Avedissian","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R18-20250410","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents.","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-20250410","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine.","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"R20-20250410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R21-20250410","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper.","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"R22-20250410","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists.","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R23-20250410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.2024.0179","article-title":"International consensus criteria for pediatric sepsis and septic shock.","volume":"331","author":"Schlapbach","year":"2024","journal-title":"JAMA"},{"key":"R24-20250410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00431-023-05272-x","article-title":"Personalized application of antimicrobial drugs in pediatric patients with augmented renal clearance: A review of literature.","volume":"183","author":"Xu","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R25-20250410","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1093\/jac\/dkac261","article-title":"Imipenem\/cilastatin\/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.","volume":"77","author":"Fratoni","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R26-20250410","doi-asserted-by":"crossref","first-page":"768438","DOI":"10.3389\/fped.2021.768438","article-title":"Ensuring sufficient trough plasma concentrations for broad-spectrum beta-lactam antibiotics in children with malignancies: Beware of augmented renal clearance!","volume":"9","author":"Andre","year":"2021","journal-title":"Front Pediatr"},{"key":"R27-20250410","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/PCC.0000000000002951","article-title":"Suboptimal beta-lactam therapy in critically ill children: Risk factors and outcome.","volume":"23","author":"Van Der Heggen","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"R28-20250410","doi-asserted-by":"crossref","first-page":"e02629-20","DOI":"10.1128\/AAC.02629-20","article-title":"Optimizing aminoglycoside dosing regimens for critically ill pediatric patients with augmented renal clearance: Convergence of parametric and nonparametric population approaches.","volume":"65","author":"Avedissian","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20250410","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: A systematic review and meta-analysis.","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"R30-20250410","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13054-021-03680-9","article-title":"Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.","volume":"25","author":"Parizkova","year":"2021","journal-title":"Crit Care"},{"key":"R31-20250410","first-page":"187","article-title":"Extended infusion of beta-lactams is associated with improved outcomes in pediatric patients.","volume":"26","author":"Zembles","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R32-20250410","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1007\/s00431-022-04570-0","article-title":"Reliability of glomerular filtration rate estimating formulas compared to iohexol plasma clearance in critically ill children.","volume":"181","author":"Dhont","year":"2022","journal-title":"Eur J Pediatr"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T13:00:33Z","timestamp":1744290033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000003698","relation":{},"ISSN":["1529-7535","1947-3893"],"issn-type":[{"value":"1529-7535","type":"print"},{"value":"1947-3893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}